| Identification | Back Directory |  [Name]
  N-[2-[[[4-(2,2-Dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(S)-glycine monosodium salt |  [CAS]
  150374-95-1 |  [Synonyms]
  SIVELESTAT SODIUM Sivelestat sodium salt Sivelestat SodiuM anhydrous sodium,2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycinesodiumsalt Glycine, N-[2-[[[4-(2,2-diMethyl-1-oxopropoxy)phenyl]sulfonyl]aMino]benzoyl]-, MonosodiuM salt n-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(s)-glycine monosodium salt sodium 2-[[[2-[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonylamino]phenyl]-oxomethyl]amino]acetate N-[2-[[[4-(2,2-Dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(S)-glycine monosodium salt USP/EP/BP |  [Molecular Formula]
  C20H21N2NaO7S |  [MOL File]
  150374-95-1.mol |  [Molecular Weight]
  456.44 |  
 | Chemical Properties | Back Directory |  [Melting point ]
  104-108 °C(Solv: water (7732-18-5)) |  [storage temp. ]
  Desiccate at RT |  [solubility ]
  DMSO (Slightly), Methanol (Slightly) |  [form ]
  Solid |  [color ]
  White to Off-White |  
 | Hazard Information | Back Directory |  [Uses]
  Treatment of acute lung injury; acute respiratory distress syndrome (elastase inhibitor). |  [Biological Activity]
  Selective  leukocyte  elastase  inhibitor  (IC  50 =  44  nM)  that  displays  no  activity  at  a  range  of  other  proteases.  Inhibits  NF-  κ  B  activation  and  LTB  4  -induced  neutrophil  transmigration in  vitro  .  Significantly  attenuates  ischemia-induced  spinal  cord  injury,  decreases  serum  cytokine  levels  and  reduces  acute  inflammatory  lung  injury in  vivo  . |  [in vivo]
 
 Sivelestat (ONO-5046, 0.021-2.1 mg/kg, intratracheally) suppresses lung hemorrhage in hamster (ID50 = 82 pg/kg) by intratracheal administration and increase of skin capillary permeability in guinea pig (ID50 = 9.6 mg/kg) by intravenous administration, both of which are induced by human neutrophil elastase[1]. 
Sivelestat (10 mg/kg, infusion via the tail vein) ameliorates lung injury after hemorrhagic shock in rats[2]. 
Sivelestat (15, 60 mg/kg, ip) prevents ischemia–reperfusion injury in the rat bladder[3].
  | Animal Model: | Male Golden hamsters, weighing 90 to 110 g[1]. |  | Dosage: | 0.021-2.1 mg/kg. |  | Administration: | Intratracheally five min before HNE injection. |  | Result: | Significantly and dosedependently suppressed the lung hemorrhage. |  
 | Animal Model: | Male Sprague-Dawley rats weighing 350-400 g[2]. |  | Dosage: | 10 mg/kg. |  | Administration: | Continuous infusion via the tail vein at 10 mg/kg/h for 60 min during the resuscitation phase. |  | Result: | Greatly suppressed lung injury, as revealed by the reduced histological damage. 
Significantly ameliorated HSR-induced lung injury. 
Markedly decreased the levels of TNF-α and iNOS gene.
  |  
 | Animal Model: | Male Sprague Dawley rats, 8 weeks old and weighing 250-320 g[3]. |  | Dosage: | 15 mg/kg or 60 mg/kg. |  | Administration: | IP. |  | Result: | Decreased the blood flow in the bladder during reperfusion phase compared to the IR group. |  
 
  |  [storage]
  Desiccate at RT |  
  
             | 
            
            
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
             |